Stock listing
KRX:028300 HLB Co., Ltd. 주가
Follow HLB Co., Ltd. into a list and get an email when it puts out news.
Share price · KRX:028300
₩27,050 KRW -100 (-0.4%)
Close on Nov 20, 2026
- Day range
- ₩26,850 – ₩27,950 KRWNov 20, 2026
- Volume
- 448,653 sharesNov 20, 2026
- Market cap
- ₩3.60T KRWAt the close on Nov 20, 2026 · price × 132.9M shares outstanding
- 52-week range
- ₩24,150 – ₩69,200 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩41.36B KRWMedian day 581,888 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:028300 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩27,050 | -100 | -0.4% | ₩27,100 | ₩27,950 | ₩26,850 | 448,653 | |
| ₩27,150 | -1,150 | -4.1% | ₩28,350 | ₩28,500 | ₩27,050 | 581,012 | |
| ₩28,300 | +200 | +0.7% | ₩27,500 | ₩29,050 | ₩27,400 | 444,593 | |
| ₩28,100 | -450 | -1.6% | ₩28,300 | ₩29,150 | ₩28,000 | 473,551 | |
| ₩28,550 | -850 | -2.9% | ₩29,450 | ₩30,150 | ₩28,500 | 582,763 | |
| ₩29,400 | -500 | -1.7% | ₩30,100 | ₩30,400 | ₩28,700 | 587,994 | |
| ₩29,900 | -350 | -1.2% | ₩29,800 | ₩30,400 | ₩29,300 | 549,959 | |
| ₩30,250 | +100 | +0.3% | ₩30,850 | ₩30,900 | ₩29,600 | 584,370 | |
| ₩30,150 | -1,100 | -3.5% | ₩30,900 | ₩31,350 | ₩29,800 | 553,052 | |
| ₩31,250 | -1,150 | -3.5% | ₩30,250 | ₩32,700 | ₩30,000 | 859,345 | |
| ₩32,400 | -1,100 | -3.3% | ₩33,800 | ₩35,400 | ₩31,900 | 1,028,056 | |
| ₩33,500 | -7,200 | -17.7% | ₩31,700 | ₩34,200 | ₩31,400 | 2,265,407 | |
| ₩40,700 | -1,000 | -2.4% | ₩41,150 | ₩41,550 | ₩40,150 | 336,136 | |
| ₩41,700 | +1,700 | +4.3% | ₩40,650 | ₩42,000 | ₩38,700 | 487,308 | |
| ₩40,000 | +300 | +0.8% | ₩39,300 | ₩40,350 | ₩38,800 | 333,623 | |
| ₩39,700 | -950 | -2.3% | ₩40,600 | ₩40,650 | ₩38,950 | 468,363 | |
| ₩40,650 | +750 | +1.9% | ₩39,950 | ₩41,200 | ₩39,950 | 364,839 | |
| ₩39,900 | +650 | +1.7% | ₩39,450 | ₩41,300 | ₩39,150 | 450,204 | |
| ₩39,250 | -2,350 | -5.6% | ₩41,000 | ₩41,100 | ₩39,250 | 411,743 | |
| ₩41,600 | +300 | +0.7% | ₩40,850 | ₩41,800 | ₩40,200 | 313,350 | |
| ₩41,300 | -1,050 | -2.5% | ₩41,850 | ₩42,350 | ₩41,150 | 388,834 | |
| ₩42,350 | -650 | -1.5% | ₩42,900 | ₩43,650 | ₩42,150 | 363,702 | |
| ₩43,000 | +50 | +0.1% | ₩42,600 | ₩43,300 | ₩41,550 | 422,605 | |
| ₩42,950 | +1,250 | +3.0% | ₩41,300 | ₩42,950 | ₩40,900 | 437,601 | |
| ₩41,700 | +950 | +2.3% | ₩40,600 | ₩42,500 | ₩40,050 | 498,137 | |
| ₩40,750 | -1,250 | -3.0% | ₩40,950 | ₩41,600 | ₩40,000 | 695,536 | |
| ₩42,000 | -2,000 | -4.5% | ₩43,600 | ₩43,600 | ₩41,350 | 687,287 | |
| ₩44,000 | -400 | -0.9% | ₩43,300 | ₩44,850 | ₩42,250 | 861,289 | |
| ₩44,400 | -1,250 | -2.7% | ₩47,550 | ₩47,550 | ₩43,900 | 963,277 | |
| ₩45,650 | -250 | -0.5% | ₩45,950 | ₩46,500 | ₩45,100 | 925,840 | |
| ₩45,900 | -1,500 | -3.2% | ₩46,350 | ₩47,850 | ₩45,450 | 1,070,602 | |
| ₩47,400 | +6,950 | +17.2% | ₩42,700 | ₩50,700 | ₩42,150 | 5,617,819 | |
| ₩40,450 | -100 | -0.2% | ₩39,900 | ₩41,050 | ₩39,450 | 701,513 | |
| ₩40,550 | -850 | -2.1% | ₩40,800 | ₩40,800 | ₩38,800 | 1,182,456 | |
| ₩41,400 | +1,250 | +3.1% | ₩39,850 | ₩43,800 | ₩37,800 | 2,047,254 | |
| ₩40,150 | +450 | +1.1% | ₩46,600 | ₩47,700 | ₩38,700 | 6,871,767 | |
| ₩39,700 | +9,150 | +30.0% | ₩39,700 | ₩39,700 | ₩39,700 | 344,213 | |
| ₩30,550 | -500 | -1.6% | ₩31,300 | ₩31,550 | ₩30,050 | 709,670 | |
| ₩31,050 | -900 | -2.8% | ₩31,950 | ₩32,150 | ₩30,850 | 576,275 | |
| ₩31,950 | +2,300 | +7.8% | ₩30,400 | ₩33,400 | ₩29,400 | 1,484,828 | |
| ₩29,650 | -2,350 | -7.3% | ₩31,950 | ₩32,200 | ₩29,400 | 1,336,430 | |
| ₩32,000 | +100 | +0.3% | ₩32,050 | ₩32,500 | ₩31,450 | 276,720 | |
| ₩31,900 | -550 | -1.7% | ₩32,850 | ₩32,850 | ₩30,900 | 369,713 | |
| ₩32,450 | +2,100 | +6.9% | ₩30,250 | ₩32,500 | ₩30,250 | 651,181 | |
| ₩30,350 | -1,100 | -3.5% | ₩30,550 | ₩30,900 | ₩30,200 | 474,128 | |
| ₩31,450 | -200 | -0.6% | ₩31,050 | ₩32,000 | ₩31,050 | 371,080 | |
| ₩31,650 | +150 | +0.5% | ₩31,250 | ₩31,750 | ₩30,300 | 746,111 | |
| ₩31,500 | -150 | -0.5% | ₩31,350 | ₩32,200 | ₩31,050 | 438,770 | |
| ₩31,650 | -1,300 | -3.9% | ₩32,950 | ₩33,000 | ₩31,650 | 605,825 | |
| ₩32,950 | -800 | -2.4% | ₩34,000 | ₩34,750 | ₩31,700 | 674,170 | |
| ₩33,750 | +950 | +2.9% | ₩33,150 | ₩34,550 | ₩33,100 | 466,294 | |
| ₩32,800 | -550 | -1.6% | ₩34,100 | ₩34,300 | ₩32,600 | 587,011 | |
| ₩33,350 | -700 | -2.1% | ₩33,250 | ₩34,200 | ₩32,650 | 637,898 | |
| ₩34,050 | -1,550 | -4.4% | ₩38,500 | ₩38,800 | ₩34,050 | 1,978,375 | |
| ₩35,600 | -400 | -1.1% | ₩35,350 | ₩37,350 | ₩34,600 | 14,616,441 | |
| ₩36,000 | +550 | +1.6% | ₩35,000 | ₩36,050 | ₩34,500 | 461,285 | |
| ₩35,450 | -1,050 | -2.9% | ₩36,250 | ₩37,150 | ₩35,200 | 799,627 | |
| ₩36,500 | -1,800 | -4.7% | ₩38,100 | ₩38,700 | ₩36,100 | 1,016,815 | |
| ₩38,300 | +450 | +1.2% | ₩37,600 | ₩38,300 | ₩36,350 | 447,488 | |
| ₩37,850 | -800 | -2.1% | ₩38,500 | ₩39,600 | ₩37,650 | 538,404 | |
| ₩38,650 | -1,250 | -3.1% | ₩39,250 | ₩39,350 | ₩37,550 | 573,253 | |
| ₩39,900 | -2,200 | -5.2% | ₩43,850 | ₩44,600 | ₩38,050 | 1,695,039 |
Splits
9 splits since 2003 · KRX:028300 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split | |
| 97-for-93 | Split | |
| 63-for-61 | Split | |
| 2-for-1 | Split | |
| 11-for-10 | Split | |
| 39-for-38 | Split | |
| 1-for-8 | Consolidation | |
| 1-for-5 | Consolidation | |
| 1-for-12 | Consolidation |
- Ticker
- KRX:028300
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
Latest news
Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Jan 30, 2026
Closed ₩54,200 (-2.3%) on Feb 2, 2026
HLB Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Jan 30, 2026 · oldest 2026
Valuation
EV/sales 36.9× against a median of 9.4×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩3.60T KRW
- P/E
- Loss
- EV/sales
- 36.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.4×
- Gross margin
- 41.7%
- Operating margin
- −94.9%
- Net margin
- −219.1%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| HLB Co., Ltd. · KRX:028300 | US$2.69B | US$2.69B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Denali Therapeutics Inc. · NASDAQ:DNLI | US$2.96B | US$2.69B | n/a | 126× | n/a | 3.2× | n/a | 0.3× | 1.30 |
| Dyne Therapeutics, Inc. · NASDAQ:DYN | US$2.90B | US$1.97B | n/a | n/a | n/a | 3.1× | n/a | 0.2× | 1.51 |
| Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180 | US$2.88B | US$2.99B | n/a | 8.0× | n/a | 3.2× | −35.0% | 0.7× | n/a |
| SELLAS Life Sciences Group, Inc. · NASDAQ:SLS | US$2.78B | US$2.65B | n/a | n/a | n/a | 21.1× | n/a | 0.0× | 2.19 |
| Celcuity Inc. · NASDAQ:CELC | US$2.62B | US$1.98B | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Zai Lab Ltd. · HKEX:9688 | US$2.60B | US$2.04B | n/a | 4.6× | n/a | 4.6× | −44.9% | 0.0× | n/a |
| Xencor, Inc. · NASDAQ:XNCR | US$2.50B | US$2.16B | n/a | 10.8× | n/a | 4.5× | −58.8% | 0.1× | 1.21 |
| IDEAYA Biosciences, Inc. · NASDAQ:IDYA | US$2.47B | US$1.66B | n/a | 45.5× | n/a | 2.3× | n/a | 0.0× | 0.96 |
| MBX Biosciences, Inc. · NASDAQ:MBX | US$2.46B | US$1.98B | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 1.30 |
| Almirall SA · BME:ALM | US$2.45B | US$2.46B | 31.1× | 1.6× | 7.3× | 1.5× | 5.1% | 0.2× | n/a |
| Median of the others | US$2.61B | US$2.10B | 31.1× | 9.4× | 7.3× | 3.2× | −40.0% | 0.1× | 1.30 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 13, 2026 · Before open | −5.5% |
| Q4 2025 | Feb 24, 2026 · Before open | +0.2% |
| Q3 2025 | Nov 12, 2025 · Before open | +3.1% |
| Q2 2025 | Aug 12, 2025 · Before open | +0.1% |
| Q1 2025 | May 15, 2025 · Before open | −0.5% |
| Q4 2024 | Feb 26, 2025 · Before open | −3.5% |
| Q3 2024 | Nov 12, 2024 · After close | +0.3% |
| Q2 2024 | Aug 14, 2024 · After close | +6.3% |
| Q1 2024 | May 14, 2024 · After close | +1.3% |
| Q4 2023 | Mar 21, 2024 · After close | −0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 14, 2023 · After close | +1.0% |
| Q2 2023 | Aug 11, 2023 · After close | −1.3% |
| Q1 2023 | May 15, 2023 · After close | −0.9% |
| Q4 2022 | Feb 17, 2023 · After close | +29.9% |
| Q3 2022 | Nov 14, 2022 · After close | −0.6% |
| Q2 2022 | Jul 20, 2022 · Before open | +4.0% |
| Q1 2022 | Apr 25, 2022 · Before open | −0.5% |
| Q4 2021 | Feb 23, 2022 · Before open | +0.7% |
| Q3 2021 | Nov 15, 2021 · Before open | +1.8% |
| Quarter to Jun 30, 2021 | Aug 13, 2021 · Before open | +4.0% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.2B | 68.1B | 42.9B | 179.7B | 69.8B | 56.2B | 38.4B | 36.2B | 23.0B | 30.1B |
| Cost of revenue | 56.5B | 56.1B | 43.8B | 113.5B | 48.8B | 45.9B | 34.5B | 29.7B | 20.8B | 25.9B |
| Gross profit | 27.7B | 12.1B | -893.5M | 66.2B | 21.1B | 10.3B | 3.94B | 6.49B | 2.19B | 4.27B |
| Research and development | 59.9B | 41.2B | 49.1B | 43.9B | 48.4B | 22.6B | 22.2B | 12.7B | 10.1B | |
| Selling, general and administrative | 29.6B | 85.7B | 67.8B | 82.0B | 62.9B | 39.7B | 17.8B | 13.3B | 15.3B | 15.0B |
| Operating income | -98.6B | -123.3B | -201.2B | -77.2B | -103.5B | -61.5B | -56.0B | -702.2M | -31.8B | -21.4B |
| Depreciation and amortization | 5.36B | 5.36B | 4.92B | 4.36B | 12.0B | 10.5B | 2.18B | 1.37B | 1.63B | 1.42B |
| EBITDA | -93.3B | -118.0B | -196.3B | -72.8B | -91.5B | -51.0B | -53.8B | 667.2M | -30.1B | -20.0B |
| Interest expense | 12.4B | 10.7B | 10.6B | 11.7B | 3.63B | 5.26B | 0 | 0 | 0 | 0 |
| Income before tax | -240.5B | -109.2B | -212.8B | -88.4B | -110.4B | -93.2B | -59.8B | 13.5B | -33.4B | -23.3B |
| Income tax | 1.16B | -4.49B | -103.2M | -17.5M | -12.0B | 0 | ||||
| Net income | -220.5B | -92.0B | -187.5B | -78.2B | -98.1B | -80.1B | -44.4B | 25.3B | -16.5B | -13.2B |
| Earnings per share, basic | -1,659.45 | -701.44 | -1,456.91 | -639.87 | -921.57 | -757.80 | -461.07 | 287.29 | -202.34 | -164.04 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 41.0B | 93.0B | 108.9B | 195.7B | 99.8B | 220.7B | 40.9B | 30.2B | 7.35B | 9.37B |
| Short-term investments | 46.8B | 45.3B | 3.08B | 109.4B | 27.3B | 3.74B | 11.1B | 806.1M | 19.5B | 8.66B |
| Receivables | 9.52B | 9.01B | 7.23B | 15.1B | 34.0B | 11.7B | 9.91B | 9.94B | 3.90B | 4.74B |
| Inventory | 9.45B | 9.69B | 11.4B | 12.3B | 13.8B | 4.87B | 4.92B | 3.86B | 4.14B | 3.85B |
| Current assets | 124.3B | 172.3B | 144.4B | 343.6B | 188.1B | 251.6B | 69.7B | 117.1B | 35.3B | 27.1B |
| Property, plant and equipment | 83.8B | 60.1B | 51.6B | 41.5B | 19.9B | 12.5B | 12.8B | 10.3B | 10.8B | |
| Goodwill | 77.8B | 39.6B | 37.8B | 65.8B | 62.3B | 31.0B | 25.0B | 28.5B | 25.9B | 26.3B |
| Total assets | 930.2B | 887.4B | 751.7B | 967.3B | 743.7B | 706.5B | 362.6B | 304.0B | 188.2B | 186.7B |
| Accounts payable | 5.39B | 5.66B | 6.99B | 3.72B | 5.08B | 3.27B | 987.1M | 1.87B | 1.40B | 1.65B |
| Current liabilities | 347.7B | 160.7B | 86.3B | 200.4B | 121.8B | 98.0B | 67.7B | 20.9B | 42.3B | 15.4B |
| Long-term debt | 58.2B | 44.4B | 17.9B | 320.0M | 47.4B | 614.0M | 74.5B | 44.0B | 4.32B | 6.06B |
| Total debt | 15.5B | 85.2B | 50.0B | 7.14B | 12.3B | |||||
| Total liabilities | 435.8B | 310.9B | 169.5B | 329.3B | 307.7B | 226.7B | 177.7B | 129.4B | 111.0B | 98.0B |
| Shareholders' equity | 418.5B | 576.6B | 523.9B | 637.9B | 436.0B | 479.8B | 184.9B | 174.7B | 77.2B | 88.7B |
| Shares outstanding | 132.9M | 131.1M | 128.7M | 122.1M | 106.5M | 105.7M | 96.3M | 88.2M | 81.7M | 80.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -92.6B | -114.3B | -111.6B | -61.8B | -54.8B | -56.5B | -48.7B | -29.2B | -19.1B | -10.2B |
| Capital spending | -17.5B | -27.1B | -7.06B | -12.6B | -2.19B | -972.2M | -1.72B | -599.7M | -1.70B | -2.42B |
| Free cash flow | -110.1B | -141.4B | -118.7B | -74.4B | -60.9B | -131.5B | -50.4B | -29.8B | -20.8B | -12.6B |
| Cash from investing | -74.8B | 25.5B | -112.3B | -68.5B | -98.0B | -26.8B | -28.2B | -13.0B | -2.89B | |
| Cash from financing | 170.3B | -3.05B | 267.6B | 1.34B | 341.0B | 86.7B | 80.0B | 30.1B | 18.0B | |
| Dividends paid | 0 | -83.6M | -83.6M | -83.6M | -83.6M | |||||
| Share buybacks | 2.01B | -4.08B | 241.1B | 786.2M | 382.7B | 29.9B | 6.01B | 1.34B | 21.0B | |
| Change in cash | -52.1B | -15.8B | -86.8B | 95.9B | -120.9B | 179.8B | 10.6B | 22.9B | -2.02B | 5.00B |
Cap table
Built by 6ix from HLB Co., Ltd.’s releases
- Common shares
- 132,941,522
- Fully diluted
- 132,941,522
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 132,941,522 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 132,941,522 |
Log in to ask 6ix AI your own questions about HLB Co., Ltd.